Treatment with caspofungin in immunocompromised paediatric patients: A multicentre survey

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 3, 2006, Pages 527-535

  Groll, Andreas H ^a   Attarbaschi, Andishe ^h   Schuster, Friedhelm R ^b   Herzog, Nadine ^c   Grigull, Lorenz ^d   Dworzak, Michael N ^h   Beutel, Karin ^e   Laws, Hans Jürgen ^f   Lehrnbecher, Thomas ^g  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Cancer; Children; Echinocandins; Immunodeficiency; Mycoses

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPHOTERICIN B; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CASPOFUNGIN; CREATININE; CYCLOSPORIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ADOLESCENT; ARTICLE; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEADACHE; HEALTH SURVEY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; METABOLIC DISORDER; MYCOSIS; NAUSEA AND VOMITING; RETROSPECTIVE STUDY; SKIN MANIFESTATION; SOLID TUMOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADOLESCENT; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; MALE; MYCOSES; PEPTIDES, CYCLIC; RETROSPECTIVE STUDIES;

EID: 32644466027     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkl009     Document Type: Article

References (37)

1. Bartizal K, Gill CJ, Abruzzo GK et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2326-32.
2. Stone JA, Holland SD, Wickersham PJ et al. Single- and multipledose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46: 739-45.
3. Sable CA, Nguyen BY, Chodakewitz JA et al. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002; 4: 25-30.
4. Villanueva A, Arathoon EG, Gotuzzo E et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33: 1529-35.
5. Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294-9.
6. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
7. Maertens J, Raad I, Petrikkos G et al. Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-71.
8. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351:1391-402.
9. Groll AH, Gea-Banacloche JC, Glasmacher A et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003; 7: 159-91.
10. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.
11. Keating G, Figgitt D. Caspofungin: A review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs 2003; 63: 2235-63.
12. Boucher HW, Groll AH, Chiou CC et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64: 1997-2020.
13. Franklin JA, McCormick J, Flynn PM. Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr Infect Dis J 2003; 22: 747-9.
14. Cesaro S, Toffolutti T, Messina C et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Haematol 2004; 73: 50-5.
15. Odio CM, Araya R, Pinto LE et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004; 23: 1093-7.
16. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
17. Kartsonis NA, Saah A, Lipka CJ et al. Second-line therapy with caspofungin for mucosal or invasive candidiasis: Results from the caspofungin compassionate-use study. J Antimicrob Chemother 2004; 53: 878-81.
18. Common Toxicity Criteria, Version 2.0. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA. http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf (April 1999, date last accessed).
19. Walsh TJ, Adamson PC, Seibel NL et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49: 4536-45.
20. Ernst EJ, Klepser ME, Ernst ME et al. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis 1999; 33: 75-80.
21. Louie A, Deziel M, Liu W et al. AUC/MIC is the pharmacodynamic variable for caspofungin as determined in a non-neutropenic mouse model of disseminated candidiasis. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2003. Abstract A-1572, p.31 American Society for Microbiology, Washington, DC, USA.
22. Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292-9.
23. Marr KA, Boeckh M, Carter RA et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802.
24. Aliff TB, Maslak PG, Jurcic JG et al. Refractory Aspergillus pneumonia in patients with acute leukemia: Successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: 1025-32.
25. Maertens J, Glasmacher A, Herbrecht R et al. Multicenter non-comparative study of caspofungin combined with other antifungals in adults with invasive aspergillosis refractory or intolerant to standard regimens. In: Abstract Addendum of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract M-671a, p. 14. American Society for Microbiology, Washington, DC, USA.
26. Seibel N, Schwartz C, Arrieta A et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005; 49: 3317-24.
27. Benjamin DK, Driscoll T, Seibel NL et al. Safety and pharmacokinetics of anidulafungin in pediatric patients with neutropenia. In: Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract A-34, p. 8. American Society for Microbiology, Washington, DC, USA.
28. Groll AH, Walsh TJ. Caspofungin: Pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001; 10: 1545-58.
29. Package circular: Cancidas® (caspofungin acetate for injection), Version February 2005. Whitehouse Station, NJ: Merck & Co., Inc.
30. Marr KA, Hachem R, Papanicolaou G et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004; 6: 110-6.
31. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004; 34: 13-20.
32. Trenschel R, Ditschkowski M, Elmaagacli AH et al. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 35: 583-6.
33. Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-96.
34. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-31.
35. Herbrecht R, Auvrignon A, Andres E et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immuno-suppressed paediatric patients. Eur J Clin Microbiol Infect Dis 2001; 20: 77-82.
36. Walsh TJ, Lutsar I, Driscoll T et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-8.
37. Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 2005; 24: 167-74.